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follow-up, all patients in each study arm remained free of any cardiac events. There were 
no target lesion revascularisatkms reported so far. 6 month follow-up aXaminatiOnS are 
expected to stalt in September 2002. At time of presentation, we will present the com- 
plete 6 month follow-up angiographic and IVUS data. 
Conclusions: The FUTURE trial represents a pioneer experience demonstrating Safety of 
the new Everolimus coated Challenge-Stent with a 100% procedural success rate and an 
uneventful in-hospital and m-day follow-up in all patients. The 6 month follow-up data will 
be presented. 
1006-184 Evaluation of a Tacrolimus-Eluting Coronary Stent With 
Nanoporous Ceramic Coating in Treatment of Native 
Coronary Artery Lesions: Phase I and II of the PRESENT 
Study 
Ulrich Gerckens. Lutz Buellesfeld. Dieter Horstkotte. Ralf Mueller, Manfred Staberock, 
Guide Selbach. Thomas Schmidt, Eberhard Grube. Healt Center Siegburg, Siegburg, 
Germany, Heart Center Bad Oeynhausen. Bad Oeynhausen, Germany 
Background: Drug eluting stents (DES)has recently emerged as one of the most promis- 
Ing techniques for intetventional treatment of coronary lesions. Tacrolimus is an antipro- 
liferative and antiinflammatory agent with proven efficacy in other therapeutical areas 
(transplant medication). The antiproliferative effect in coronary applications is selectively 
focused on smooth muscle cell activities rathsr than inhibition of endothelial cell prolifera- 
tion. To evaluate both safety and feasibility of a Tacrolimus eluting stent, which utilizes a 
nanoporous aluminium oxide ceramic as drug carrier, the PRESENT study have been 
conducted.Methods and Results: The PRESENT Study is a prospective study, evaluat- 
ing the ceramic coated coronary stent with and without Tacrolimus in treatment of native 
coronary de-nova lesions with 30 patients in each arm. Primary endpoint was 30-day 
safety defined as absence of MACE. Angiographic and IVUS follow-up was scheduled at 
6 months after index procedure. The interim analysis after enrollment of 22 and 2 
patients with DES and contol stent implantation, respectively, showed absence of in-hos- 
pital and 30.day MACE in each group; however, 3 target vessel revascularisations 
beyond the 30 day period in the group of DES were observed and the trial was halted 
(phase I). After modification of the stent design with increase in drug dosages loaded on 
the DES, the trial was restarted evaluating the bare ceramic coated stent and the modi- 
fied high dose drug eluting stent in 30 patients each (phase II). To date, 24 patients in the 
high dose DES group has been enrolled without any adverse cardiac events after DES 
implantation. At time of presentation, complete procedural and 30 day follow-up data of 
the phase I and II patient population as well as B-month angiographic and IVUS data will 
be presented. 
Conclusion: The PRESENT trial demonstrates safety and feasibility of a new ceramic 
coated coronary stent with and without elution of Tacrolimus. The need of target vessel 
revascularisations in the low dose group (phase I) might suggest an inappropriate drug 
loading of the first stem version. Phase II with high dose Tacrolimus will clarify the effi- 
cacy of this concept in treatment of coronary lesions. 
1006-185 Evaluation of the BiodivYsio Stent With Matrix HI 
Coating Designed for Local Drug Delivery in Coronary 
Arteries: A Randomized Trial 
Helmut SchOhler$ Adnan Kastrati, Julinda Mehilli, J&g Hausleiter, Jiirgen Pache, Josef 
Dirschinger, Albert Schbmig. Deutsches Herzzentrum. Munich, Germany, 1. Med. Klinik 
rechts der Isar. Munich, Germany 
Background: Stent coating integrating an active drug for local delivery is currently 
Intensely investigated to prevent restenosis after coronary stent placement. Stem design, 
surface, and as shown in the ISAR-STEREO l&2 trials, strut thickness have a significant 
impact on restenosis. The commercially available BiodivYsio stent is a thin-strut stent 
(9Opm) with a phosphorylcholine coating (PC) with favorable long-term results as shown 
by the SOPHOS trial. The standard PC coating has been modified to allow local delivery 
of biomolecules (batimastat. angiopeptin and others). Goal of the present study was to 
evaluate the efficacy of the BiodivYsiostent with this Matrix HI polymer coating (MBIO) 
without an active drug, by comparison with the Guidant RX MultiLink (ML) which was the 
stent with the lowest restenosis rate in both ISAR-STEREO trials. 
Methods & Results: Patients with symptomatic coronary artery disease (acute coronary 
syndrome in 36.7%) were randomly asslgned to either the MBIO (n=142) or the ML 
(n=l42). Baseline clinical and angiographic characteristics did not differ significantly 
between the 2 groups; vessel size was 3.OOi.54 (MBIO) vs. 3.06+.50mm (ML), lesion 
length 13.2+6.9 vs. 13.1&.9mm. Number of stents implanted (1.3k.9 vs. 1.3+.6), bal- 
loon/vessel ratio (1.16+.12 vs. 1.16~.13), and final %-diameter stenosis (5.629.7 vs. 
5.OA6.9) did not differ significantly. Repeat angiography (performed in 60% of eligible 
pts.) revealed restenosis (~50% diameter stenosis) in 37.3% with MBIO and 17.3% with 
ML (pc.OOl), late loss was 1.17*.75 vs 0.98+.63mm (p=.O4). After 1 year, target vessel 
revascularization was done in 22.5 vs. 13.4% (pz.04). the rate of death or myocardial inf- 
arction was not signiftcantly different (4.9 vs. 4.9%). 
Conclusions: In this randomized comparison, the BiodivYsiostent with Matrix HI poly- 
mer coating (without active drug) has less favorable results. As the restenosis rate for the 
standard PC-coated BiodivYsio was much lower in the SOPHOS trial (17.7%). these 
data suggest a negative effect of the Matrix HI polymer coating. This needs to be 
accounted for when designing and interpreting studies with this stem coating. 
1006-l 86 Titanium Nitride-Oxide Coated Stent: Six-Month 
Angiographic and Intravascular Ultrasound Follow-Up 
Christophe Caussin Marie-Jeanne Alibelli, Meyer Elbaz, Martial Hamon, Gilles Grollier, 
Philippe Commeau, Bernard Lancelin, C.C. Marie Lannelongue. Le Plessis Robinson, 
France 
Titanium nitride oxyde (Ti-NO) is biologically inert has an excellent biocompatibility 
exemplified by the lack of a redox and hydrolysis reaction as well as an absent complex 
metal ion-organic molecule binding formation. Ti-NO coated stent has significantly 
reduced neointimal proliferation compared to stainless steel stent in pigs. The aim of our 
study was to prospectively evaluate the feasibility and safety of a Ti-NO stainless steel 
coated stem (Helistent @, Hexacath, France) in humans. 
Inclusion criteria were a single lesion less than15 mm in length in a native coronary artery 
with a reference diameter between 3.0 and 4.0 mm eligible for PCI. Exclusion criteria 
were high-grade calcifications, ostial or bifurcation lesion, less than 72 hours acute myo- 
cardial infarction. Clinical follow-up was performed at one month and angiographic fol- 
low-up was systematically performed at six months. QCA and IVUS analysis were 
centralized. 
133 patients were included in the study. 40 pts were selected for post implantation and 
six months IVUS analysis. Mean age was 62.4 * 11.4 y. Prior history of diabetes was 
19%. CABG :I%, PCI: 5%. MI 19%. Clinical presentation was unstable angina : 43%, 
stable angina: 23%. post Ml : 17%, silent ischemia: 17%. ACC/AHA classification lesion 
was A:29%, B: 71%. Reference diameter with QCA analysis was 3.21* 0.36mm. MLD 
pre and post stent were I.142 0.32 and 2.99+ 0.35mm. Post implantation IVUS reference 
diameter was 4.32+/- 0.45mm, reference area was 14.61+/-2.57mm2, stent symetry was 
0.9+/-0.03 and stent lumen cross section area was 9.01+/-2.05mm2. Success rate 
implantahon was 100%. In hospital events was one death due to per-procedure aortic 
dissection, one regressive stroke and two groin haematomas. At one month no subacute 
thrombosis, no TLR and no Ml was observed. 
In conclusion immediate and one month follow-up results are very promising. Six months 
angiographic and IVUS follow-up is ongoing, complete results will be communicated dur- 
ing the presentation. 
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1007-l 73 Incidence of Renal Artery Stenosis in 2,111 Patients 
Undergoing Coronary Angiography: A Model of 
Predictive Risk of Renal Artery Stenosis 
Grayson G. Geary,David J. Tanous David L. Ross, Westmead Hospital, Sydney, 
Australia 
Background: Renal artery stenosis (RAS) is an important cause of hypertension and 
ischemic renal disease and should be identified in patients (pts) where possible. Data on 
the predictive risk of RAS at the time of coronary angiography for different patient profiles 
is lacking. Our aim was to determine the incidence of RAS in a large group of pts under- 
going coronary angiography and to develop a model to determine the risk of RAS for any 
subgroup of pts. Methods: A total of 2111 consecutive pts were screened for RAS with a 
contrast injection in the descending aorta after the ventriculogram. Multiple risk factors 
were assessed. Results: RAS was present in 1% of pts without CAD and in 13% of pts 
with CAD. Independent risk factors for RAS in pts with CAD were age (Odds ratio (OR) 
l.O5/year, p<O.OOl), female sex (OR 1.91, p<O.OOl), peripheral vascular disease (PVD) 
(OR 2.32, p<O.OOl), cerebrovascular disease (CVD) (OR 1.60, p&05), 3 vessel disease 
(OR 3.14. p<O.OOl) and hypertension (OR 1.56, p=O.Ol). A model was developed utlliz- 
ing these risk factors which enables the prediction of RAS in different patient profiles. An 
example is shown for males aged 60 with hypertension and CAD. Conclusions: RAS was 
rare in pts without CAD. In pts with CAD, there was a relatively high Incidence of unsus- 
pected RAS (13%). In pts with CAD and RAS there was a high incidence of other vascu- 
lar disease. The incidence of RAS in pts with CAD can be predicted using the model 
developed and may aid in determining which pts should be screened. 
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